Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)

Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)

Dettagli Bibliografici
Autori principali:	Dutton, S, Blazeby, J, Petty, R, Mansoor, W, Thompson, J, Harrison, M, Abbas, H, Dahle-Smith, A, Chatterjee, A, Falk, S, Garcia-Alonso, A, Fyfe, D, Hubner, R, Gamble, T, Peachey, L, Harvey, C, Julier, P, Jankowski, J, Midgley, R, Ferry, DR, Grp, C
Natura:	Journal article
Pubblicazione:	2013

Documenti analoghi

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
di: Dutton, S, et al.
Pubblicazione: (2014)

Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer
di: Petty, R, et al.
Pubblicazione: (2017)

Gefitinib and EGFR gene copy number aberrations in esophageal cancer
di: Petty, RD, et al.
Pubblicazione: (2017)

Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
di: Mei-Chuan Tang, et al.
Pubblicazione: (2015-01-01)

Busting the Breast Cancer with AstraZeneca’s Gefitinib
di: S. Chemmalar, et al.
Pubblicazione: (2023-01-01)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
di: Harada Masao, et al.
Pubblicazione: (2007-03-01)

Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells
di: Shuang Zhao, et al.
Pubblicazione: (2021-11-01)

Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
di: Norihiro Kikuchi, et al.
Pubblicazione: (2003-01-01)

Mucocutaneous side effects of gefitinib
di: Ruhaila Thekkath, et al.
Pubblicazione: (2021-01-01)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
di: Jun Li, et al.
Pubblicazione: (2020-02-01)

Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer
di: Honggang Wang, et al.
Pubblicazione: (2017-07-01)

Gefitinib-induced pyogenic granuloma in a patient with lung cancer
di: Satyajeet Sahoo, et al.
Pubblicazione: (2020-01-01)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
di: Takuya Araki, et al.
Pubblicazione: (2012-01-01)

Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
di: T Brown, et al.
Pubblicazione: (2010-10-01)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
di: Hongbo Zhao, et al.
Pubblicazione: (2018-11-01)

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
di: Horak, J, et al.
Pubblicazione: (2011)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
di: Shu Y, et al.
Pubblicazione: (2021-11-01)

VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION
di: Midgley, R, et al.
Pubblicazione: (2008)

Pyogenic Granuloma in a Patient on Gefitinib
di: António Fernandes Massa, et al.
Pubblicazione: (2016-06-01)

Predicting Tumor Responses to Gefitinib and Erlotinib.
Pubblicazione: (2005-01-01)

Triggering of Suicidal Erythrocyte Death by Gefitinib
di: Abdulla Al Mamun Bhuyan, et al.
Pubblicazione: (2017-03-01)

Urinary Neopterin in Patients Treated with Gefitinib
di: Kalabova Hana, et al.
Pubblicazione: (2007-02-01)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
di: Tatsuya Nagano, et al.
Pubblicazione: (2011-01-01)

Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma
di: Brown, N, et al.
Pubblicazione: (2016)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
di: Nicholas Brown, et al.
Pubblicazione: (2016-01-01)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
di: Iwao Shimomura, et al.
Pubblicazione: (2013-01-01)

Design of gefitinib-loaded PLGA microspheres via microfluidics for lung cancer
di: Ruohan Huang, et al.
Pubblicazione: (2023-10-01)

Drug delivery systems of gefitinib for improved cancer therapy: A review
di: Deepak Nagdiya, et al.
Pubblicazione: (2023-11-01)

Gefitinib for Non-small Cell Lung Cancer: A meta Analysis
di: Jiwu GUO, et al.
Pubblicazione: (2011-04-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
di: Yung-Hung Luo, et al.
Pubblicazione: (2015-09-01)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
di: Takuya Araki, et al.
Pubblicazione: (2013-01-01)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
di: Pietro Carotenuto, et al.
Pubblicazione: (2011-03-01)

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer
di: Xiao Ling Ni, et al.
Pubblicazione: (2017-01-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
di: Zhonghan Zhang, et al.
Pubblicazione: (2019-11-01)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
di: Yuan Ying, et al.
Pubblicazione: (2012-11-01)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib.
Pubblicazione: (2012-03-01)

Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
di: Sacchi Ada, et al.
Pubblicazione: (2010-02-01)

Gefitinib: Combination Therapy and Complex Delivery Systems (Review)
di: L. L. Nikolaeva, et al.
Pubblicazione: (2024-03-01)

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
di: Chien-Hung Gow, et al.
Pubblicazione: (2005-09-01)

Cellular photo(geno)toxicity of gefitinib after biotransformation
di: Meryem El Ouardi, et al.
Pubblicazione: (2023-06-01)